Valuation
- Market cap
- 16,693,610,000
- Revenue TTM
- $2,530,230,000
- Net income TTM
- $451,120,000
- PE ratio
- 36.59
- Forward PE
- 35.59
- Profit margin
- 17.83%
- Debt to equity
- 0.00
Trading
- Volume
- 303,600
- Avg volume
- 253,632
- Day's range
- $587.39 – $609.75
- Shares out
- 27,912,000
- Stochastic %K
- 24%
- Beta
- 1.18
- Analysts
- Sell
- Price target
- $610.77
Company profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries;...
Show more
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 513 579 9911
- Website
- https://www.medpace.com
- Address
- 5375 Medpace Way, Cincinnati, United States
Latest news
No headlines yet.